SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Sunesis Pharmaceuticals, Inc. Merger

Rigrodsky & Long, P.A.
·1-min read

WILMINGTON, Del., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Sunesis Pharmaceuticals, Inc. (“Sunesis”) (NASDAQ CM: SNSS) regarding possible breaches of fiduciary duties and other violations of law related to Sunesis’ agreement to merge with Viracta Therapeutics, Inc. (“Viracta”). Under the terms of the agreement, Sunesis will issue a number of shares of Sunesis common stock to stockholders of Viracta.

To learn more about this investigation and your rights, visit:

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.


Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530